Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Royal Caribbean Cruises Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Royal Caribbean Cruises Ltd trades at $281.14 (market cap $75.70B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 16.9× ACADIA Pharmaceuticals Inc.'s market cap, and Royal Caribbean Cruises Ltd pays a 1.77% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | RCL | |
|---|---|---|
Market Cap | $4.49B | $75.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $365.84 |
52-Week Low | $20.06 | $246.71 |
Enterprise Value | $3.69B | $96.98B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Royal Caribbean (RCL) trades at $282.26, down 4.74% on the day, showing bearish technical momentum but maintaining strong fundamentals. The company reported robust Q1 2026 earnings of $3.60 per share, beating expectations, with revenue growth accelerating from $16.5B in 2024 to $17.9B in 2025. Analyst consensus remains positive with a $325.10 price target, though technical indicators signal near-term caution with support at $283.
RCL presents a compelling investment case with strong profitability (50.41% ROE) and consistent earnings beats, though elevated debt levels and fuel cost sensitivity pose risks. The stock's current pullback near key support levels offers potential entry points for long-term investors seeking exposure to the recovering cruise industry with disciplined financial management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
